T
Thomas C. Merigan
Researcher at Stanford University
Publications - 515
Citations - 34283
Thomas C. Merigan is an academic researcher from Stanford University. The author has contributed to research in topics: Interferon & Virus. The author has an hindex of 98, co-authored 514 publications receiving 33941 citations. Previous affiliations of Thomas C. Merigan include University of Arizona & Rockefeller Institute of Government.
Papers
More filters
Journal ArticleDOI
Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy
John D. Baxter,Thomas C. Merigan,Deborah Wentworth,James D. Neaton,Marie L. Hoover,Richard M. W. Hoetelmans,Stephen C. Piscitelli,Werner Verbiest,Douglas L. Mayers,Douglas L. Mayers +9 more
TL;DR: In salvage therapy, both the number of active drugs and the DL for each drug in the new regimen determine the antiviral response.
Journal ArticleDOI
Thermal activation of the antiviral activity of synthetic double-stranded polyribonucleotides.
TL;DR: Preincubation at 37 °C rendered various alternating ribonucleotide copolymers and homopolyribon nucleotide pairs significantly more active in reducing vesicular stomatitis virus plaque formation in human skin fibroblasts.
Journal ArticleDOI
β Interferon Produced by Keratinocytes in Human Cutaneous Infection with Herpes Simplex Virus
TL;DR: One host response associated with inhibiting the dissemination of HSV infection is the production of interferon (IFN).
Journal Article
Syngeneic monoclonal anti-idiotype antibodies that bear the internal image of a human cytomegalovirus neutralization epitope.
TL;DR: Syngeneic monoclonal anti-Id antibodies of the IgM isotype are produced that bear the internal image of the original viral antigen as shown by their ability to recognize an interspecies idiotype in CMV-positive human antisera and block CMV neutralization by mAb1 in vitro.
Journal ArticleDOI
Two Double-Blinded, Randomized, Comparative Trials of 4 Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Vaccines in HIV-1—Infected Individuals across a Spectrum of Disease Severity: AIDS Clinical Trials Groups 209 and 214
Robert T. Schooley,Cathie Spino,Daniel R. Kuritzkes,Bruce D. Walker,Fred T. Valentine,Martin S. Hirsch,Elizabeth L. Cooney,Gerald Friedland,Smriti K. Kundu,Thomas C. Merigan,M. Juliana McElrath,Ann C. Collier,Susan Plaeger,Ronald T. Mitsuyasu,James O. Kahn,Patrick Haslett,Patricia Uherova,Victor DeGruttola,Simon Chiu,Bin Zhang,Gayle Jones,Dawn Bell,Nzeera Ketter,Thomas Twadell,David Chernoff,Mary E. Rosandich +25 more
TL;DR: These studies were undertaken to define patient populations most likely to respond to vaccination, with the induction of novel HIV-1-specific cellular immune responses, and to compare the safety and immunogenicity of several candidate recombinant HIV- 1 envelope vaccines and adjuvants.